• 中国资本市场开放出大招 跨境证券投资更便利 2019-10-13
  • 世卫将“游戏障碍”列为新疾病 哪些症状可被确诊? 2019-10-13
  • 景区去门票化积弊短期难除 如何摆脱门票依赖? 2019-10-08
  • 东风路老旧小区欲华丽变身 微改造项目勘察设计已招标 ——凤凰网房产广州 2019-10-08
  • 翔龙无人机服役后首次曝光,大幅提升空军情报收集能力 2019-09-19
  • 证监会去年对外公开监管信息14560条 2019-09-19
  • 人民网欧洲中心分社记者报道集 2019-09-06
  • 图解:短视频平台频遭约谈敲响警钟,野蛮生长要不得! 2019-09-06
  • 中考期间广州部分公交线路有调整 2019-09-01
  • 减肥必备!这十种食物饱口福还能吃出好身材 2019-09-01
  • “蛟龙” 吸引世界目光(砥砺奋进的五年·重大工程巡礼) 2019-08-19
  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 来宝网Logo

    热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

    现在位置时时彩网络平台>技术资料首页>行业动态>公司动态>欧洲首个iPS专利获批 iPS战场硝烟四起

    峡谷重案组第一季全集: 欧洲首个iPS专利获批 iPS战场硝烟四起

    iPierian2010年2月2日 20:23 点击:2517

    时时彩网络平台 www.qlgr.net 美国 iPierian
    科技的竞技场是一个没有硝烟的战场,却有着与战争类似的残酷竞争,获胜的唯一法宝是占得先机,取得专利权,再生医学领域中最热门的竞技场无外乎于“诱导多能干细胞iPS”这个战场。继日本京都大学山中伸弥首次申请iPS专利后,一家生物科技公司也不甘示弱,申请iPS专利权,这是欧洲第一个被批准的iPS专利权。

     

     

    第一个iPS专利权花落山中伸弥家

     

    2008年9月13日,日本京都大学日前宣布,该校教授山中伸弥开发的诱导多功能干细胞(iPS细胞)培养方法已被日本特许厅(相当于专利局)授予专利,成为世界首个获得批准的iPS细胞相关专利。

     

    获批的专利内容是“将4种基因植入普通体细胞,可使体细胞转变成拥有分化为各种组织细胞能力的iPS细胞”,专利有效期到2026年12月。京都大学希望通过在日本国内获得专利,造成既定事实,从而在与欧美研究人员的竞争中抢得先机。

     

     

    生物医学公司iPierian在英国获得iPS专利权

     

    iPierian公司是2009年7月 iZumi Bio, Inc.与Pierian, Inc.合并而成的新公司,这所新公司合并后将致力于细胞重编的应用,从而改变药物发现的模式。该公司在科技领域的领导地位将加快新疗法的开发,从而将诱导功能干细胞 (iPS) 应用于疑难病患者。

     

    2010年1月12日英国知识产权办公室(UK Intellectual Property Office)授予iPierian公司iPS技术专利权,他们认为神户的一位科学家Kazuhiro Sakurada才是iPS的创始人,山中伸弥不是,而Kazuhiro Sakurada早期在iZumi Bio, Inc.任首席科学家职务。早在2008年iPierian公司便对外宣称,他们该获得iPS的相关专利。

     

     

    山中伸弥Kazuhiro Sakurada与iPierian公司关系复杂

     

    山中伸弥曾在加州大学的一个实验室做iPS试验,试验的经费来自iPierian公司。

     

    Kazuhiro Sakurada早期在iZumi Bio, Inc.任首席科学家职务,Sakurada在2007年6月就已经向日本专利局申请iPS专利,可是直到山中伸弥取得专利权后Sakurada才取得专利权。

     

    Sakurada与山中伸弥所申请的iPS技术不同,山中伸弥用的是4个转录因子,而Sakurada用的是3个,没有用那个致癌的C-Myc基因。早在2007年Sakurada就已经建立iPS细胞系,只是他的研究结果到2008年1月才发表。

     

    京都大学发言人Akemi Nakamura在新闻发布会上对此事件表示抗议,他们认为,山中伸弥才是iPS的创始人,iPS专利应该由京都大学的实验室获得。

    关于iPierian, Inc.

     

    iPierian, Inc.以 iZumi 的基础架构和使命为基础,这个新公司将致力于细胞重编的应用,从而改变药物发现的模式。该公司在科技领域的领导地位将加快新疗法的开发,从而将诱导功能干细胞 (iPS) 应用于疑难病患者。

     

    iPierian正以iZumi经验丰富的管理和科技团队为基础快速发展,该团队在干细胞科技和药物发现领域拥有丰富的知识经验。该公司将由 iZumi 现任首席执行官 John P. Walker 领导。Berta Strulovici 博士将担任 iPierian 的首席技术官,主管研究工作,而 Dushyant Pathak 博士将领导该公司的业务开发活动。最近曾担任辉瑞 (Pfizer) 生物疗法与生物创新中心总裁Corey Goodman 博士将担任 iPierian 董事长。Corey Goodman还是美国国家科学院 (US National Academy of Sciences) 的当选院士,以及iZumi董事会成员。

     

    Pierian 科技业务创始人、哈佛学(Harvard University)教师 George Daley 博士、Douglas Melton 博士和 Lee Rubin 博士将积极参与 iPierian 有关科研方向和研究重点的决策制定。Daley 博士将与 Deepak Srivastava 博士共同担任 iPierian 科学顾问委员会 (SAB) 主席。Deepak Srivastava 现任 Gladstone Institute of Cardiovascular Disease 主管兼加州大学旧金山分校 (University of California San Francisco, UCSF) 教授。Corey Goodman 博士还将担任该公司科学顾问委员会会员,与一干领先的干细胞科学家共事。

     iPierian新闻稿

    First iPierian Patent for Induced Pluripotent Stem Cell Technology Granted by United Kingdom Intellectual Property Office

     

    South San Francisco, CA – January 28, 2010- iPierian, Inc., a biopharmaceutical company focused on changing the paradigm of drug discovery and development through the application of cellular reprogramming, today announced that the Intellectual Property Office in the United Kingdom has issued a Notification of Grant to iPierian for UK patent No. GB2450603, its first patent related to induced pluripotent stem cell (iPSC) technology.

    The newly granted UK patent covers the generation of human iPS cells from human postnatal cells through any combination of forced expression of genes that includes the Oct3/4, Sox2 and Klf4 genes, so long as the combination does not include c-Myc. The elimination of c-Myc, a potentially cancer causing gene, has been an early goal of researchers in the field as an important step so that iPSC technology may one day be employed as a therapeutic for the treatment of disease. The resulting human iPS cells have in vitro long-term self-renewal ability and can differentiate into ectoderm, mesoderm and endoderm.

    “This is the first patent protecting a fundamental method and utility of human iPSC technology that has been granted outside of Japan. As such, this is an important milestone for both iPierian and for the field of human cellular reprogramming,” said John P. Walker, chief executive officer of iPierian. “The UK patent grant is a first step in our strategy to broadly develop and prosecute our intellectual property throughout the world. We will continue to pursue additional patents in the UK, US, Europe and other important jurisdictions for both the fundamental invention of human iPS cells and other technologies we are developing as a result of our research and development efforts.

    “iPierian is dedicated to applying its technology for the benefit of patients as well as encouraging further research in the field of cellular reprogramming. We look forward to continuing our model of collaboration with leading academic institutions as we believe this patent could be of great use to universities conducting cutting edge research in the United Kingdom,” concluded Walker.

    Following the Notification of Grant, the patent is typically announced in the UK Patents Journal and the company expects this publication to occur in February. The grant has already been posted to the United Kingdom Intellectual Property Office website at //www.ipo.gov.uk/p-find-number/patents?csbpub=GB2450603&csbtype=F.

    This patent is based upon the innovative research led by Dr. Kazuhiro Sakurada, former Head of Global Drug Discovery Regenerative Medicine Bayer Schering Pharma AG. Under an agreement in 2008, the Sakurada patent estate related to iPSC technology was assigned to iZumi Bio, now iPierian.
     

    About iPierian
    iPierian is a South San Francisco-based biopharmaceutical company focused on the industrialization of induced pluripotent stem cell (iPSC) technology with the mission of creating new therapeutics through cellular reprogramming and directed differentiation of patient cells. iPierian is backed by Kleiner Perkins Caufield & Byers, Highland Capital Partners, MPM Capital and FinTech Global Capital. The initial focus of the company is in neurodegeneration, particularly spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease, metabolic disease and cardiovascular disease, where iPierian has a collaboration with The Gladstone Institute of Cardiovascular Disease and Dr. Deepak Srivastava, the institute’s director and co-chair of the iPierian scientific advisory board (SAB). In 2009, the company announced a formal collaboration with the laboratory of Dr. Shinya Yamanaka of Kyoto University to develop and improve methods of deriving iPS cell lines in order to advance iPSC technology. The company’s SAB is comprised of leading researchers and authorities in the stem cell field including individuals from the University of California and Harvard University where the co-chair of the SAB, Dr. George Daley is an associate professor.

    Because iPS cells are believed to be able to grow indefinitely in culture and to differentiate into many cell types, iPS cells have great potential for disease research, preclinical drug testing and cell-based therapy. iPierian’s approach places the patient at the forefront of the drug discovery process in order to reduce drug development time and increase the probability of success for drug candidates. iPierian plans to use precise human disease models to find new molecular targets and develop proprietary small molecule or biologic therapeutics.
    (来源: iPierian )


    全年征稿 / 资讯合作

    联系邮箱:[email protected]

    版权与免责声明

    • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, 时时彩网络平台,违反者本网将追究相关法律责任。
    • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
    • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


  • 中国资本市场开放出大招 跨境证券投资更便利 2019-10-13
  • 世卫将“游戏障碍”列为新疾病 哪些症状可被确诊? 2019-10-13
  • 景区去门票化积弊短期难除 如何摆脱门票依赖? 2019-10-08
  • 东风路老旧小区欲华丽变身 微改造项目勘察设计已招标 ——凤凰网房产广州 2019-10-08
  • 翔龙无人机服役后首次曝光,大幅提升空军情报收集能力 2019-09-19
  • 证监会去年对外公开监管信息14560条 2019-09-19
  • 人民网欧洲中心分社记者报道集 2019-09-06
  • 图解:短视频平台频遭约谈敲响警钟,野蛮生长要不得! 2019-09-06
  • 中考期间广州部分公交线路有调整 2019-09-01
  • 减肥必备!这十种食物饱口福还能吃出好身材 2019-09-01
  • “蛟龙” 吸引世界目光(砥砺奋进的五年·重大工程巡礼) 2019-08-19
  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 新疆25选7历史开奖结果 678线上娱乐城 新疆18选7连线走势图 内蒙11选五开奖结果 25选5是什么彩票 体彩河南11选5玩法 浙江11选5胆拖复式投注表 竞彩棒球比赛得分算加时 电子游戏有人赢过吗 网上免费挣钱 3串1混合过关 江苏快3投注技巧去哪查 广东快乐10分投注网 澳客网足球彩票胜负彩足球彩票 12112期20选5